Immunological erythroblastopenia induced by HCO-60 as a solvent of enocitabine (BH-AC).
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002368:Castor Oil / Q000009:adverse effects / Q000031:analogs & derivatives*; D003561:Cytarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004900:Erythroblasts / Q000187:drug effects* / Q000276:immunology; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000276:immunology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D008297:Male; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000276:immunology; D012997:Solvents / Q000009:adverse effects*
D012997:Solvents; D003561:Cytarabine; C023040:polyethoxylated castor oil; D002368:Castor Oil; C015019:enocitabine